KRAS and pachyonychia congenita: Correspondingly, PC patients with KRAS mutant ctDNA were more likely to relapse after curative surgery than those without KRAS mutant ctDNA with desease-free survival of 6.1 versus 16.1 months and overall survival of 13.6 versus 27.6 months (p < 0.001) (Groot et al. 2019; Hadano et al. 2016; Sausen et al. 2015).